NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$11.13 USD
-0.38 (-3.30%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.14 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
NovoCure Limited's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
NVCR 11.13 -0.38(-3.30%)
Will NVCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCR
NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
NVCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
What Makes NovoCure (NVCR) a New Buy Stock
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Other News for NVCR
NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead
Insider Buying: Christoph Brackmann Acquires 20,000 Shares of NovoCure Ltd (NVCR)
NovoCure's Wearable Oncology Edge And Compelling Valuation
Top 3 Health Care Stocks That May Explode In July
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Target Cut | NVCR Stock News